{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:13:12Z","timestamp":1790982792746,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"DOPPS Program"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,10]]},"abstract":"\n Background<\/jats:title>\n The prospective Dialysis Outcomes and Practice Patterns Study (DOPPS) has collected data since 2012 in all six Gulf Cooperation Council (GCC) countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates). We report the relationship of PTH with mortality in this largest GCC cohort of patients on hemodialysis studied to date.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Data were from randomly selected national samples of hemodialysis facilities in GCC-DOPPS phases 5 and 6 (2012\u20132018). PTH descriptive findings and case mix\u2013adjusted PTH\/mortality Cox regression analyses were based on 1825 and 1422 randomly selected patients on hemodialysis, respectively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Mean patient age was 55 years (median dialysis vintage, 2.1 years). Median PTH ranged from 259 pg\/ml (UAE) to 437 pg\/ml (Kuwait), with 22% having PTH <150 pg\/ml, 24% with PTH of 150\u2013300 pg\/ml, 34% with PTH 301\u2013700 pg\/ml, and 20% with PTH >700 pg\/ml. Patients with PTH >700 pg\/ml were younger; on dialysis longer; less likely to be diabetic; have urine >200 ml\/d; be prescribed 3.5 mEq\/L dialysate calcium; had higher mean serum creatinine and phosphate levels; lower white blood cell counts; and more likely to be prescribed cinacalcet, phosphate binders, or IV vitamin D. A U-shaped PTH\/mortality relationship was observed with more than two- and 1.5-fold higher adjusted HR of death at PTH >700 pg\/ml and <300 pg\/ml, respectively, compared with PTH of 301\u2013450 pg\/ml.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Secondary hyperparathyroidism is highly prevalent among GCC patients on hemodialysis, with a strong U-shaped PTH\/mortality relationship seen at PTH <300 and >450 pg\/ml. Future studies are encouraged for further understanding this PTH\/mortality pattern in relationship to unique aspects of the GCC hemodialysis population.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000772020","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T20:35:16Z","timestamp":1598474116000},"page":"1083-1090","source":"Crossref","is-referenced-by-count":25,"title":["Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012\u20132018)"],"prefix":"10.34067","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-5972","authenticated-orcid":false,"given":"Issa","family":"Al Salmi","sequence":"first","affiliation":[{"name":"The Royal Hospital, Ministry of Health, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bieber","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Rukhaimi","sequence":"additional","affiliation":[{"name":"Dubai Medical College, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"AlSahow","sequence":"additional","affiliation":[{"name":"Jahra Hospital, Jahra, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faissal","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed M.G.","family":"Al-Ghamdi","sequence":"additional","affiliation":[{"name":"King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Al Wakeel","sequence":"additional","affiliation":[{"name":"King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadwa","family":"Al Ali","sequence":"additional","affiliation":[{"name":"Hamad General Hospital, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Aradi","sequence":"additional","affiliation":[{"name":"Salmaniya Medical Complex, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez Al","family":"Hejaili","sequence":"additional","affiliation":[{"name":"King Saud Bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacoub Al","family":"Maimani","sequence":"additional","affiliation":[{"name":"The Royal Hospital, Ministry of Health, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"Fouly","sequence":"additional","affiliation":[{"name":"Amgen United Arab Emirates, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Pisoni","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.108.808733","article-title":"Plasma parathyroid hormone and the risk of cardiovascular mortality in the community","volume":"119","author":"Hagstr\u00f6m","year":"2009","journal-title":"Circulation"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1053\/j.ajkd.2013.08.011","article-title":"Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: Evidence from marginal structural models used to adjust for time-dependent confounding","volume":"63","author":"Fukagawa","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.ajkd.2012.04.001","article-title":"The DOPPS practice monitor for US dialysis care: Trends through August 2011","volume":"60","author":"Pisoni","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12882-018-1056-5","article-title":"Mineral and bone disorder management in hemodialysis patients: Comparing PTH control practices in Japan with Europe and North America: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Yamamoto","year":"2018","journal-title":"BMC Nephrol"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2004.12.011","article-title":"Secondary hyperparathyroidism: Review of the disease and its treatment","volume":"26","author":"de Francisco","year":"2004","journal-title":"Clin Ther"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"c159","DOI":"10.1159\/000099006","article-title":"Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities","volume":"105","author":"Khan","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"c91","DOI":"10.1159\/000335979","article-title":"Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: The Japan dialysis outcomes and practice pattern study","volume":"120","author":"Inaba","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12882-016-0382-8","article-title":"Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis","volume":"17","author":"Block","year":"2016","journal-title":"BMC Nephrol"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.xkme.2019.04.004","article-title":"International and racial differences in mineral and bone disorder markers and treatments over the first 5 years of hemodialysis in the dialysis outcomes and practice patterns study","volume":"1","author":"Chan","year":"2019","journal-title":"Kidney Med"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1525-139X.2001.00043.x","article-title":"The dialysis outcomes and practice patterns study (DOPPS): How can we improve the care of hemodialysis patients?","volume":"14","author":"Goodkin","year":"2001","journal-title":"Semin Dial"},{"issue":"Suppl 1","key":"B14-20230821","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/1319-2442.194878","article-title":"The dialysis outcomes and practice patterns study phase 5 in the Gulf Cooperation Council countries: Design and study methods","volume":"27","author":"Pisoni","year":"2016","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.publhealth.25.102802.124410","article-title":"What do we do with missing data? Some options for analysis of incomplete data","volume":"25","author":"Raghunathan","year":"2004","journal-title":"Annu Rev Public Health"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/sim.4780100410","article-title":"Multiple imputation in health-care databases: An overview and some applications","volume":"10","author":"Rubin","year":"1991","journal-title":"Stat Med"},{"issue":"Suppl","key":"B17-20230821","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0272-6386(03)00372-X","article-title":"Cardiovascular complications in chronic kidney disease","volume":"41","author":"Sarnak","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1525-139X.2003.16028.x","article-title":"Traditional cardiac risk factors in individuals with chronic kidney disease","volume":"16","author":"Uhlig","year":"2003","journal-title":"Semin Dial"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","article-title":"Cardiovascular outcomes and all-cause mortality: Exploring the interaction between CKD and cardiovascular disease","volume":"48","author":"Weiner","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"E638","DOI":"10.1210\/jc.2012-4007","article-title":"Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: The Hoorn study","volume":"98","author":"van Ballegooijen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B21-20230821","first-page":"gin\/31.6.4","article-title":"[Parathormone and left ventricular hypertrophy]","volume":"31","author":"Massimetti","year":"2014","journal-title":"G Ital Nefrol"},{"key":"B22-20230821","first-page":"2019","article-title":"[Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy]","volume":"36","author":"Massimetti","year":"2019","journal-title":"G Ital Nefrol"},{"key":"B23-20230821","first-page":"67","article-title":"Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis","volume":"31","author":"Nasri","year":"2004","journal-title":"Acta Med Austriaca"},{"key":"B24-20230821","first-page":"318","article-title":"Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients","volume":"54","author":"Block","year":"2000","journal-title":"Clin Nephrol"},{"issue":"Suppl 1","key":"B25-20230821","first-page":"i2","article-title":"The pathophysiology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: The role of COSMOS","volume":"1","author":"Cannata-And\u00eda","year":"2008","journal-title":"NDT Plus"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","article-title":"The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease","volume":"17","author":"Goodman","year":"2004","journal-title":"Semin Dial"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am J Nephrol"},{"issue":"Suppl 1","key":"B28-20230821","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/1319-2442.194902","article-title":"Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012\u20132015) [published correction appears in Saudi J Kidney Dis Transpl 28: 1452, 2017 10.4103\/1319-2442.220972]","volume":"27","author":"Al Salmi","year":"2016","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/hdi.12503","article-title":"Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons","volume":"21","author":"Bikbov","year":"2017","journal-title":"Hemodial Int"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.2011.948","article-title":"Mortality in chronic kidney disease and mineral metabolism","volume":"306","author":"Floege","year":"2011","journal-title":"JAMA"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2369-14-88","article-title":"Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis","volume":"14","author":"Natoli","year":"2013","journal-title":"BMC Nephrol"},{"key":"B35-20230821","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2215\/CJN.03930416","article-title":"Facility practice variation to help understand the effects of public policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"12","author":"Fuller","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","article-title":"Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study","volume":"26","author":"Naves-D\u00edaz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B37-20230821","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/ki.2010.189","article-title":"Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals","volume":"78","author":"Kalantar-Zadeh","year":"2010","journal-title":"Kidney Int Suppl"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/j.ajkd.2015.07.011","article-title":"The DOPPS practice monitor for US dialysis care: PTH levels and management of mineral and bone disorder in US hemodialysis patients","volume":"66","author":"Tentori","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B40-20230821","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","article-title":"Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients","volume":"12","year":"2008","journal-title":"Ther Apher Dial"},{"key":"B41-20230821","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"B42-20230821","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"B43-20230821","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"B44-20230821","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.04260413","article-title":"CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis","volume":"8","author":"Block","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B45-20230821","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2369-13-116","article-title":"Mineral and bone disorder in Chinese dialysis patients: A multicenter study","volume":"13","author":"Kong","year":"2012","journal-title":"BMC Nephrol"},{"key":"B46-20230821","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2015.12.001","article-title":"Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients","volume":"89","author":"Merle","year":"2016","journal-title":"Kidney Int"},{"key":"B47-20230821","first-page":"397","article-title":"Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment","volume":"13","author":"Joy","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"B48-20230821","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","article-title":"VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH \u2264 150 pg\/mL: Results of the Italian FARO survey","volume":"27","author":"Cozzolino","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B49-20230821","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/jbmr.177","article-title":"Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients","volume":"25","author":"Kalantar-Zadeh","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B50-20230821","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01760408","article-title":"Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients","volume":"3","author":"Shinaberger","year":"2008","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000772020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:58:15Z","timestamp":1786478295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000772020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000772020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}